Research never stops


Jan 19, 2017

Evotec enters into an integrated drug discovery collaboration with Asahi Kasei Pharma (Japan)

Hamburg, Germany, 19 January 2017: Evotec AG today announced it has entered into an integrated drug discovery collaboration on an ion channel target with Asahi Kasei Pharma Corporation, a wholly owned subsidiary of Asahi Kasei Corporation, Tokyo, Japan.

- read more
Jan 17, 2017

Evotec and MaRS Innovation establish strategic partnership to launch Fibrocor Therapeutics

Toronto, Canada and Hamburg, Germany, 17 January 2017: Evotec AG and MaRS Innovation today announced the launch of Fibrocor Therapeutics LP ("Fibrocor"), a Toronto-based company focused on developing first-in-class therapeutics targeting fibrotic diseases.

- read more
Jan 12, 2017

HaplogenĀ“s novel antiviral target partnered with Evotec published in 'Nature'

Vienna/Amsterdam/Hamburg, 12 January 2017: Evotec AG  today announced a promising research result in the field of picornaviruses published in a scientific article by Dr Thijn Brummelkamp, the co-founder of Haplogen GmbH, a biotech company based in Vienna, Austria, that develops antiviral therapeutics in a co-owned partnership with Evotec.

- read more
Jan 09, 2017

Evotec and Eternygen to develop novel metabolic disease therapy

Hamburg, Germany, 09 January 2017: Evotec AG announced today that it will extend its existing relationship with Eternygen GmbH by becoming an investor in addition to being a pre-clinical drug discovery partner.

- read more